|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial
|
Gwenaëlle Gravis Mescam, MD
Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial, 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Early Triplet Combination Therapy Shows Increased Overall Survival: The ARASENS Trial
|
|
Tomasz Beer, MD, FACP
|
| Alicia Morgans is joined by Tomasz Beer for a discussion on the ARASENS trial, an international, double-blind, phase 3 study that enrolled patients with mHSPC and ECOG performance status 0 or 1.
|
|
|
|
|
|
|
|
|
|
|
|
|
A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient
|
|
Neal Shore, MD, FACS
|
| Neal Shore joins Alicia Morgans in discussing the approval of NUBEQA® (darolutamide) in the metastatic hormone-sensitive setting in combination with docetaxel on ADT.
|
|
|
|
|
|
|
|
|
|
|
|
|
Treatment Intensification Strategies in mHSPC: Triplets and More
|
|
Christopher Sweeney, MBBS
|
| Christopher Sweeney presents treatment intensification strategies in metastatic hormone-sensitive prostate cancer (mHSPC), focusing on triplet therapies. |
|
|
|
|
|
|
|
|
|
|
|
| Third or Fourth Place in the Race? No Problem – The Case for More Trials Using Darolutamide for Patients with Prostate Cancer
|
| Evan Yu, MD
|
| Darolutamide first received regulatory approval for patients with non-metastatic (M0) castration-resistant prostate cancer based on the results of the ARAMIS trial. Although apalutamide and enzalutamide were regulatory approved prior to darolutamide, all three agents were successful in demonstrating both metastasis-free and overall survival benefit in their respective randomized phase 3 trials over placebo.
|
|
|
|
|
|
| Metastatic Castration-Sensitive Prostate Cancer 2022 Updates Discussion
|
| Boris Hadaschik, MD
|
| Boris Hadaschik discusses two abstracts, “Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal burden as a prognostic biomarker -ancillary studies of the docetaxel and abiraterone acetate and prednisolone phase III trials from STAMPEDE”. As well as, “8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase 3 trial”.
|
|
|
|
|
|
|
|
|
|
|
| Effect of Abiraterone-Prednisone in mCSPC with Neuroendocrine and Very High-Risk Features in the PEACE-1 Trial
|
| Alice Bernard-Tessier, MD
|
| The 2022 European Society of Medical Oncology (ESMO) annual meeting featured a prostate cancer session, including a presentation by Alice Bernard-Tessier discussing the results of the PEACE-1 trial, specifically the effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer with neuroendocrine and very high-risk features.
|
|
|
|
|
|
| Triple Combination Therapy With Chemohormonal Approaches: Paving a Path Forward in Various Disease States With Newer Agents and Even More Treatment Intensification
|
| Evan Yu, MD
|
| It seems likely that a new standard of care for patients eligible for docetaxel chemotherapy, certainly those with “high-volume” or “high-risk” disease, will begin to receive chemohormonal therapy with ADT, docetaxel and either darolutamide or abiraterone acetate. Yet there are still valid questions surrounding “triple combination therapy.”
|
|
|
|
|
|
| What Is the Evidence of Systemic Therapies (Alone or in Combination With MDT) in Oligometastatic mHSPC?
|
| Mary Ellen Taplin, MD
|
| Mary Ellen-Taplin discusses the role of systemic therapy in this disease state. Currently, there remains a need to better understand the biology within this disease space to guide biomarker design and discover and identify optimal treatment approaches.
|
|
|
|
|
|
|
